Design Therapeutics, Inc. ((DSGN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Design Therapeutics, Inc. is conducting a clinical study titled ‘A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Patients With Friedreich’s Ataxia.’ The study aims to evaluate the safety and pharmacokinetics of DT-216P2, a potential treatment for Friedreich’s Ataxia, a rare genetic disorder.
The intervention being tested is DT-216P2, a drug administered via subcutaneous and intravenous routes. It is designed to assess its safety and tolerability in patients, potentially offering a new therapeutic option for those affected by Friedreich’s Ataxia.
This interventional study follows a sequential model without masking, focusing on treatment as its primary purpose. It is structured to progressively test increasing doses of DT-216P2 to gather comprehensive safety data.
The study began on February 25, 2025, with the latest update submitted on May 14, 2025. These dates mark the study’s initiation and ongoing progress, critical for tracking its development and potential outcomes.
The update on this study could influence Design Therapeutics’ stock performance positively, as successful results might enhance investor confidence and market position. It is crucial to monitor this study alongside industry trends and competitors’ advancements in similar therapeutic areas.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.